At the news
? BULLISHIMPACT 7/10 8-K filed Jun 30, 2026 at 07:31 ET
Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M in total consideration ($70M upfront cash plus up to $70M in future revenue-based milestones). The deal includes collaboration on a spasticity program. Proceeds will be used to repay Pacira's senior secured revolving credit facility, strengthening its balance sheet. This divestiture advances Pacira's transition into a pure biopharmaceutical company focused on non-opioid therapies.
- Pacira to receive $70M upfront cash for the iovera divestiture to Zimmer Biomet
- Total potential consideration up to $140M including $70M in revenue-based milestone payments through 2031
- Upfront proceeds to be used to pay down Pacira's senior secured revolving credit facility
- 66 employees (~8% of workforce) expected to transfer to Zimmer Biomet at closing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access